Evidence map›Paper›PMID 35969285›Full record

ArticleBreast cancer research and treatment2022

Dose-dependent relation between metformin and the risk of hormone receptor-positive, her2-negative breast cancer among postmenopausal women with type-2 diabetes.

Soumya G Chikermane, Manvi Sharma, Susan M Abughosh, Rajender R Aparasu, Meghana V Trivedi, Michael L Johnson

Abstract read
PubMed Publisher
In one paragraph

Article in Breast cancer research and treatment, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Soumya G ChikermaneDepartment of Pharmaceutical Health Outcomes and Policy, University of Houston, Houston, TX, USA.
Manvi SharmaDepartment of Pharmacy Administration, School of Pharmacy, The University of Mississippi, 235 Faser Hall, Oxford, MS, 38677, USA. manvi.uh@gmail.com.ORCID http://orcid.org/0000-0002-4221-7801
Susan M AbughoshDepartment of Pharmaceutical Health Outcomes and Policy, University of Houston, Houston, TX, USA.
Rajender R AparasuDepartment of Pharmaceutical Health Outcomes and Policy, University of Houston, Houston, TX, USA.
Meghana V TrivediDepartment of Pharmaceutical Practice and Translational Research, University of Houston, Houston, TX, USA.
Michael L JohnsonDepartment of Pharmaceutical Health Outcomes and Policy, University of Houston, Houston, TX, USA.
University of Houston · USUniversity of Mississippi · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeMetformin has demonstrated a chemoprotective effect in breast cancer but there is limited evidence on the effect of cumulative exposure to metformin and the risk of hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR + /HER2-) breast cancer. This study assessed this risk with dose and intensity of metformin in postmenopausal women with type-2 diabetes mellitus (T2DM).

methodsThis nested case-control study used the Surveillance, Epidemiology, and End Results-Medicare data (2008-2015). Cohort entry was the date of incident T2DM diagnosis. Cases were those diagnosed with HR + /HER2- breast cancer (event date) as their first/only cancer. Non-cancer T2DM controls were matched using variable-ratio-matching. Cumulative dose and average intensity of metformin were measured during the 1-year lookback period. Dose(mg) was categorized as: (1)0, (2)0-30,000, (3)30,001-136,000, (4)136,001-293,000, and (5) > 293,000, and intensity(mg/day) as: 0, 1-500, and > 500. Covariates were conceptualized using the Andersen Behavioral Model. Conditional logistic regression was used to assess the risk of HR + /HER2- breast cancer with metformin-use.

resultsThere were 690 cases and 2747 controls. The median duration of T2DM was 1178 days in controls and 1180 days in cases. Higher cumulative dose categories: 4 (adjusted odds ratio(aOR) = 0.72, 95% CI 0.55-0.95,p = 0.02), and 5 (OR = 0.60, 95% CI 0.42-0.85,p < 0.01) had significantly lower odds of HR + /HER2- breast cancer compared to category 0. The highest intensity category of metformin had 39% lower odds of HR + /HER2- breast cancer (OR = 0.61, 95% CI 0.46-0.82,p < 0.01) compared to the 0 mg/day group.

conclusionsHigher metformin exposure was associated with reduced risk of HR + /HER2- breast cancer, adding to the evidence supporting metformin's chemoprotective effect.

Indexed as

Breast NeoplasmsDiabetes Mellitus, Type 2MetforminAgedCase-Control StudiesErb-b2 Receptor Tyrosine KinasesFemaleHumansMedicarePostmenopauseUnited StatesErb-b2 Receptor Tyrosine KinasesMetforminBreast cancer riskChemopreventionMetforminPostmenopausal womenType-2 diabetes

Identifiers

PMID35969285
OpenAlexW4291785915

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.